Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $6.65, up 57.96% on the session, giving a market capitalisation of $382.4M. On trailing twelve-month figures it carries a trailing P/E of -2.71, a net margin of 0.0%. Its beta of 0.53 implies it has historically moved less than the broad market.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Capricor Therapeutics, Inc. is most often compared with the following Healthcare names: